New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer

Donna P Ankerst, Ian M. Thompson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In this paper, we report ongoing investigations concerning the increased number of high-grade (Gleason grade ≥ 7) prostate cancer, despite a reduction in all prostate cancer, found on the finasteride arm of the Prostate Cancer Prevention Trial (PCPT). There was a statistically significant 24.8% reduction in prostate cancer found on biopsy on the finasteride arm compared to placebo, and the reduction was also observed in both groups of end-of-study and for-cause biopsies. However, when the prostate cancers were examined by Gleason score, there was an increased number of high-grade prostate cancers found on the finasteride arm than on the placebo arm. This observation was emphasized in the editorial to the first publication of PCPT results and has dampened enthusiasm for recommendation of finasteride for chemoprevention. So, what are the potential reasons for increased grade on the finasteride arm? The number of high-grade cancers that are detected following a PSA prompt is directly proportional to the sensitivity of PSA for high-grade disease times the actual but unknown number of high-grade disease cases. So the higher the sensitivity the more likely one is to detect more of the existing high-grade cases irrespective of the true number of cases, i.e., there is an ascertainment bias. We are currently performing a quantitative investigation of whether or not this ascertainment bias could explain the higher number of high-grade disease cases observed on the finasteride arm.

Original languageEnglish (US)
Pages (from-to)154-156
Number of pages3
JournalArchivio Italiano di Urologia e Andrologia
Volume78
Issue number4
StatePublished - Dec 2006

Fingerprint

Finasteride
Chemoprevention
Prostatic Neoplasms
Placebos
Biopsy
Neoplasm Grading
Publications
Neoplasms

Keywords

  • Chemoprevention
  • PCPT
  • Prostate cancer
  • PSA

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer. / Ankerst, Donna P; Thompson, Ian M.

In: Archivio Italiano di Urologia e Andrologia, Vol. 78, No. 4, 12.2006, p. 154-156.

Research output: Contribution to journalArticle

@article{b8d69b9f243d490486b0c3f4b92c3559,
title = "New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer",
abstract = "In this paper, we report ongoing investigations concerning the increased number of high-grade (Gleason grade ≥ 7) prostate cancer, despite a reduction in all prostate cancer, found on the finasteride arm of the Prostate Cancer Prevention Trial (PCPT). There was a statistically significant 24.8{\%} reduction in prostate cancer found on biopsy on the finasteride arm compared to placebo, and the reduction was also observed in both groups of end-of-study and for-cause biopsies. However, when the prostate cancers were examined by Gleason score, there was an increased number of high-grade prostate cancers found on the finasteride arm than on the placebo arm. This observation was emphasized in the editorial to the first publication of PCPT results and has dampened enthusiasm for recommendation of finasteride for chemoprevention. So, what are the potential reasons for increased grade on the finasteride arm? The number of high-grade cancers that are detected following a PSA prompt is directly proportional to the sensitivity of PSA for high-grade disease times the actual but unknown number of high-grade disease cases. So the higher the sensitivity the more likely one is to detect more of the existing high-grade cases irrespective of the true number of cases, i.e., there is an ascertainment bias. We are currently performing a quantitative investigation of whether or not this ascertainment bias could explain the higher number of high-grade disease cases observed on the finasteride arm.",
keywords = "Chemoprevention, PCPT, Prostate cancer, PSA",
author = "Ankerst, {Donna P} and Thompson, {Ian M.}",
year = "2006",
month = "12",
language = "English (US)",
volume = "78",
pages = "154--156",
journal = "Archivio Italiano di Urologia Andrologia",
issn = "1124-3562",
publisher = "Edizioni Scripta Manent s.n.c.",
number = "4",

}

TY - JOUR

T1 - New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer

AU - Ankerst, Donna P

AU - Thompson, Ian M.

PY - 2006/12

Y1 - 2006/12

N2 - In this paper, we report ongoing investigations concerning the increased number of high-grade (Gleason grade ≥ 7) prostate cancer, despite a reduction in all prostate cancer, found on the finasteride arm of the Prostate Cancer Prevention Trial (PCPT). There was a statistically significant 24.8% reduction in prostate cancer found on biopsy on the finasteride arm compared to placebo, and the reduction was also observed in both groups of end-of-study and for-cause biopsies. However, when the prostate cancers were examined by Gleason score, there was an increased number of high-grade prostate cancers found on the finasteride arm than on the placebo arm. This observation was emphasized in the editorial to the first publication of PCPT results and has dampened enthusiasm for recommendation of finasteride for chemoprevention. So, what are the potential reasons for increased grade on the finasteride arm? The number of high-grade cancers that are detected following a PSA prompt is directly proportional to the sensitivity of PSA for high-grade disease times the actual but unknown number of high-grade disease cases. So the higher the sensitivity the more likely one is to detect more of the existing high-grade cases irrespective of the true number of cases, i.e., there is an ascertainment bias. We are currently performing a quantitative investigation of whether or not this ascertainment bias could explain the higher number of high-grade disease cases observed on the finasteride arm.

AB - In this paper, we report ongoing investigations concerning the increased number of high-grade (Gleason grade ≥ 7) prostate cancer, despite a reduction in all prostate cancer, found on the finasteride arm of the Prostate Cancer Prevention Trial (PCPT). There was a statistically significant 24.8% reduction in prostate cancer found on biopsy on the finasteride arm compared to placebo, and the reduction was also observed in both groups of end-of-study and for-cause biopsies. However, when the prostate cancers were examined by Gleason score, there was an increased number of high-grade prostate cancers found on the finasteride arm than on the placebo arm. This observation was emphasized in the editorial to the first publication of PCPT results and has dampened enthusiasm for recommendation of finasteride for chemoprevention. So, what are the potential reasons for increased grade on the finasteride arm? The number of high-grade cancers that are detected following a PSA prompt is directly proportional to the sensitivity of PSA for high-grade disease times the actual but unknown number of high-grade disease cases. So the higher the sensitivity the more likely one is to detect more of the existing high-grade cases irrespective of the true number of cases, i.e., there is an ascertainment bias. We are currently performing a quantitative investigation of whether or not this ascertainment bias could explain the higher number of high-grade disease cases observed on the finasteride arm.

KW - Chemoprevention

KW - PCPT

KW - Prostate cancer

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=33846289982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846289982&partnerID=8YFLogxK

M3 - Article

VL - 78

SP - 154

EP - 156

JO - Archivio Italiano di Urologia Andrologia

JF - Archivio Italiano di Urologia Andrologia

SN - 1124-3562

IS - 4

ER -